Vaxart, Inc.
VXRTOTCHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $237.3M | $28.7M | $7.4M | $107,000 | $892,000 | $2.9M |
| Operating income | $18.1M | −$66.3M | −$83.3M | −$114.6M | −$72.8M | −$30.2M |
| Net income | $16.3M | −$66.9M | −$82.5M | −$107.8M | −$70.5M | −$1.3M |
| Total assets | $186.1M | $166.4M | $91.8M | $153.8M | $221.2M | $152.6M |
| Total liabilities | $98.3M | $107.5M | $34.0M | $43.3M | $33.6M | $29.2M |
| Equity | $87.8M | $58.9M | $57.8M | $110.6M | $187.5M | $123.4M |
| EPS (diluted) | $0.07 | $-0.33 | $-0.57 | $-0.84 | $-0.58 | — |
| Shares out. | 227.9M | 173.9M | 135.6M | 125.8M | 117.8M | 70.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 7.6%
- Net margin
- 6.9%
- Return on equity
- 18.6%
- Return on assets
- 8.8%
- Return on capital (ROCE)
- 18.2%
- Liabilities / assets
- 52.8%
- Debt / equity
- 1.12×
- Book value / share
- $0.39
- Revenue growth (YoY)
- 726.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -4.73distress
- Accruals / assets
- 4.6%clean
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Sep 15, 2014
- NT 10-Kmissed a reporting deadline ↗Sep 13, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-05-01A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
- Phase 2Active Not Recruitingreadout ~2026-11A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Sio Capital Management, LlcPassive (13G)Apr 8, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.7M | 2.8 | -9.0% |
| Apr 30, 2026 | 2.9M | 3.5 | -4.0% |
| Apr 15, 2026 | 3.0M | 5.0 | +0.9% |
| Mar 31, 2026 | 3.0M | 3.0 | -7.9% |
| Mar 13, 2026 | 3.3M | 2.6 | -10.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 19, 2026
- Results of operationsMay 7, 2026
- Director / officer change · Regulation FD disclosureApr 23, 2026
- Other material eventApr 21, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureApr 17, 2026
- Results of operationsMar 12, 2026
- Terminated a material agreementDec 29, 2025
- Results of operationsNov 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- DEFA14ADEFINITIVE ADDITIONAL MATERIALSJun 1, 2026
- ARSJun 1, 2026
- DEFA14ADEFINITIVE ADDITIONAL MATERIALSJun 1, 2026
- DEFA14ADEFINITIVE ADDITIONAL MATERIALSJun 1, 2026
- DEFC14APROXY STATEMENTJun 1, 2026
- PRER14APROXY STATEMENTMay 29, 2026
- PRRN14AMay 29, 2026
- 4FORM 4May 26, 2026
- PREC14AMay 21, 2026
- 4FORM 4May 21, 2026
- DEFA14ASOLICITING MATERIAL PURSUANT TO 240.14A-12May 20, 2026
- DEFA14ASOLICITING MATERIAL PURSUANT TO 240.14A-12May 20, 2026
- PREC14APROXY STATEMENTMay 19, 2026
- DEFA14ACURRENT REPORTMay 19, 2026
- 8-KCURRENT REPORTMay 19, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.